The FDA approved Roche’s cobas HPV test for first-line screening of cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid, commonly used in Pap tests.

Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 ...

(RTTNews) - Biopharmaceutical company Roche Holding AG (RHHBY), announced on Tuesday that its cobas HPV test for use on the cobas 6800/8800 Systems has been awarded the World Health Organization (WHO) ...

Add Yahoo as a preferred source to see more of our stories on Google. Let's be honest: Pap smears are terrible. Every year, I stare at the ceiling and try my hardest to ignore the scraping of my ...

The Roche cobas HPV Test has been approved by the FDA. A new HPV screening test that uses cervical cells collected for a Pap test has been approved by the FDA. The FDA has approved the Roche cobas HPV ...

A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...

More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection 1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; ...

The FDA approved a new self-collection test to detect human papillomavirus (HPV) and identify women at risk for cervical cancer, maker Roche announced on Wednesday. "HPV self-collection offers an ...

Roche Diagnostics is looking to a new screening tool to help women learn in a more private way if they are at increased risk for cervical cancer—a self-collection test to identify HPV. With the test, ...